View Future GrowthPasithea Therapeutics 과거 순이익 실적과거 기준 점검 0/6Pasithea Therapeutics 의 수입은 연평균 -31.3%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 30%의 비율로 증가했습니다. 매출은 연평균 67.3%의 비율로 감소해 왔습니다.핵심 정보-31.31%순이익 성장률-5.44%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률-67.26%자기자본이익률-36.99%순이익률n/a최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesPasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1Apr 21Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant MorbidityApr 01Pasithea Therapeutics Corp. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing RuleFeb 21Pasithea Therapeutics Provides Outlook on Pas-004 Clinical Programs and Data Release TimelinesJan 13Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $59.934847 million.Dec 02Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering.Nov 27Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataNov 25Pasithea Therapeutics Corp. Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsNov 22+ 1 more updateNew minor risk - Share price stability Nov 20Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $10 million.Nov 19Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Site At University of Alabama At Birmingham for Ongoing Phase 1/1B Trial of Pas-004 in Adult Nf1 PatientsNov 06Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsSep 16Pasithea Therapeutics Corp. Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsSep 08New major risk - Financial position Aug 15Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJul 31Pasithea Therapeutics Corp., Annual General Meeting, Sep 03, 2025Jul 16Pasithea Therapeutics Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price RequirementJun 29Pasithea Therapeutics Appoints James Lee to Scientific Advisory BoardJun 11Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 At the ASCO Annual Meeting 2025Jun 02Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 15Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.999522 million.May 09Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004May 08Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering.May 01Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApr 30Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingApr 24Pasithea Therapeutics Corp. Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApr 13New major risk - Shareholder dilution Mar 26New major risk - Financial position Mar 25New minor risk - Share price stability Feb 05Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation from Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced CancerFeb 05Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million.Nov 27Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNov 20New major risk - Financial position Nov 15Pasithea Therapeutics Corp. announced that it has received $5.000003 million in fundingOct 01Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in fundingSep 27Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardSep 03New minor risk - Share price stability Jul 30Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialJun 15Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024May 17Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated CancersApr 25Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004Feb 14Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJan 10Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer PatientsJan 02New major risk - Financial position Nov 20Pasithea Therapeutics Corp. Selects PAS-003 Lead Development CandidateNov 10Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023Oct 27High number of new and inexperienced directors Oct 20Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery ProgramAug 02Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more updateNew major risk - Share price stability Jul 21Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.Jun 07Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price RequirementJan 26Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea TherapeuticsDec 08Price target decreased to US$2.30 Nov 16Less than half of directors are independent Nov 16Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp Nov 02Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek TherapeuticsOct 14Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.Oct 13+ 1 more updateCamac Partners LLC Sends a Letter to Pasithea Therapeutics CorpSep 30Less than half of directors are independent Sep 23Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of DirectorsSep 21Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory BoardSep 16Camac Partners Provides Information to Shareholders of Pasithea TherapeuticsSep 09+ 1 more updateCamac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special MeetingAug 26Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple SclerosisAug 12Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special MeetingAug 06Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics CorpJul 29We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn RateJul 21Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics CorpJul 02Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics CorpJun 28Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics CorpJun 17Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes AwayJun 11Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics CorpJun 02Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022May 14Less than half of directors are independent Apr 27Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn SituationApr 06Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory BoardFeb 10Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisFeb 04Pasithea Therapeutics Corp. announced that it has received $30.38 million in fundingNov 30Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in fundingNov 26Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.KNov 24매출 및 비용 세부 내역Pasithea Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:KTTA 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-209830 Sep 250-137730 Jun 250-137731 Mar 250-147731 Dec 240-147730 Sep 240-167930 Jun 240-168931 Mar 240-168931 Dec 230-168830 Sep 230-159630 Jun 230-159631 Mar 230-1410431 Dec 220-1210330 Sep 220-79130 Jun 220-48031 Mar 220-36031 Dec 210-25030 Sep 210-330양질의 수익: KTTA 은(는) 현재 수익성이 없습니다.이익 마진 증가: KTTA는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: KTTA은 수익성이 없으며 지난 5년 동안 손실이 연평균 31.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 KTTA의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: KTTA은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(40.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: KTTA는 현재 수익성이 없으므로 자본 수익률이 음수(-36.99%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 14:48종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pasithea Therapeutics Corp.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sara NikH.C. Wainwright & Co.
Pasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1Apr 21
Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant MorbidityApr 01
Pasithea Therapeutics Corp. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing RuleFeb 21
Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $59.934847 million.Dec 02
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataNov 25
Pasithea Therapeutics Corp. Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsNov 22+ 1 more update
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $10 million.Nov 19
Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Site At University of Alabama At Birmingham for Ongoing Phase 1/1B Trial of Pas-004 in Adult Nf1 PatientsNov 06
Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsSep 16
Pasithea Therapeutics Corp. Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsSep 08
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJul 31
Pasithea Therapeutics Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price RequirementJun 29
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 At the ASCO Annual Meeting 2025Jun 02
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 15
Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.999522 million.May 09
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004May 08
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApr 30
Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingApr 24
Pasithea Therapeutics Corp. Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApr 13
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation from Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced CancerFeb 05
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million.Nov 27
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNov 20
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardSep 03
Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialJun 15
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated CancersApr 25
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004Feb 14
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJan 10
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer PatientsJan 02
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery ProgramAug 02
Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more update
Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.Jun 07
Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price RequirementJan 26
Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.Oct 13+ 1 more update
Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple SclerosisAug 12
Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special MeetingAug 06
Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics CorpJul 02
Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn SituationApr 06
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisFeb 04
